Monitoring of Cisplatin Ototoxicity by Distortion-Product Otoacoustic Emissions

Cisplatin is one of the most commonly used chemotherapeutic agents. However, ototoxicity, in particular, damage to the outer hair cells of the cochlea, is one of its major side effects. Otoacoustic emissions are acoustical signals that originate from the contractile activity of the outer hair cells....

Full description

Saved in:
Bibliographic Details
Published in:Auris, nasus, larynx nasus, larynx, 1996, Vol.23 (1), p.147-151
Main Authors: Ozturan, Orhan, Jerger, James, Lew, Henry, Lynch, Garrett R.
Format: Article
Language:English
Subjects:
Acoustic Stimulation
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Audiometry, Pure-Tone
Cisplatin - adverse effects
Cisplatin - pharmacology
Cisplatin - therapeutic use
Cochlea - physiopathology
Hair Cells, Auditory - drug effects
Hearing Disorders - diagnosis
Hearing Disorders - etiology
Humans
Male
Middle Aged
Prostate - pathology
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cisplatin is one of the most commonly used chemotherapeutic agents. However, ototoxicity, in particular, damage to the outer hair cells of the cochlea, is one of its major side effects. Otoacoustic emissions are acoustical signals that originate from the contractile activity of the outer hair cells. They are transmitted from the cochlea to the external ear canal via the middle ear apparatus. Testing is quick, painless, objective, and non-invasive. Distortion-product otoacoustic emissions (DPOAEs) are one of the evoked types of otoacoustic emissions. They are quite sensitive to any insult to the outer hair cells, even before damage is manifested in pure tone audiometry (PTA). A patient, who was on cisplatin chemotherapy due to prostate cancer, was monitored periodically for ototoxicity using DPOAEs and PTA. DPOAEs were found to detect ototoxicity one course of chemotherapy earlier than PTA during cisplatin chemotherapy. The clinical application and sensitivity of DPOAEs in monitoring ototoxicity were discussed.
ISSN:0385-8146
1879-1476
DOI:10.1016/S0385-8146(96)80023-X